October 20, 2014

GlaxoSmithKline K.K.
Sumitomo Dainippon Pharma Co., Ltd.

Announcement of termination of co-promotion of anti-depressant, Paxil
®

CR Tablets
GlaxoSmithKline K.K. (President: Philippe Fauchet, Head Office: Shibuya-ku, Tokyo) and
Sumitomo Dainippon Pharma Co., Ltd. (President: Masayo Tada, Head Office: Chuo-ku,
Osaka) announced today that the companies have reached an agreement to terminate the
co-promotion of GlaxoSmithKline K.K
’s anti
-depressant Paxil
®
CR Tablets 12.5mg and
Paxil
®
CR Tablets 25mg (paroxetine hydrochloride hydrate, hereinafter referred to as Paxil
®

CR, CR stands for Controlled Release) as of end of December 2014.

The co-promotion activity by the 2 companies was started in April 2012, with the objective
of accelerating the providing and collecting of proper prescribing information on Paxil
®
CR,
so that this medication can support patients suffering from depression.

From January 2015, GlaxoSmithKline K.K. will solely be responsible for providing
information on Paxil
®
CR.

GlaxoSmithKline K.K. and Sumitomo Dainippon Pharma Co., Ltd. will continue to
contribute to medicine through providing and collecting of proper prescribing information of
individual products.
Contacts:
GlaxoSmithKline K.K.
Corporate Communications
TEL: +81-3-5786-5030
URL: http://glaxosmithkline.co.jp/
Sumitomo Dainippon Pharma Co., Ltd.
Corporate Communications
TEL: +81-6-6203-1407 (Osaka)

+81-3-5159-3300 (Tokyo)
URL: http://www.ds-pharma.com/